key: cord-1028537-t7km9t1i authors: Khuroo, Mohammad Sultan; Sofi, Ahmad A; Khuroo, Mohammad title: Chloroquine and Hydroxychloroquine in Coronavirus Disease 2019 (COVID-19). Facts, Fiction & the Hype. A Critical Appraisal. date: 2020-07-17 journal: Int J Antimicrob Agents DOI: 10.1016/j.ijantimicag.2020.106101 sha: 05d09a47fdfd6659a37068076901d5fb9c4d9869 doc_id: 1028537 cord_uid: t7km9t1i The coronavirus infection (COVID-19) has turned in to a global catastrophe and there is an intense search for effective drug therapy. Of all the potential therapies, chloroquine and hydroxychloroquine have been the focus of tremendous public attention. Both drugs have been used in the treatment and prophylaxis of malaria and long-term use of hydroxychloroquine is the cornerstone in the treatment of several auto-immune disorders. There is convincing evidence that hydroxychloroquine has strong in vitro antiviral activity against SARS-CoV-2. Few small uncontrolled trials and several anecdotal reports have shown conflicting results of such drug therapy in COVID-19. However, as of today, the results of large scale randomized controlled trials are not available. Despite the lack of such evidence, hydroxychloroquine is used as a desperate attempt for prophylaxis and treatment of COVID-19. The drug has wide-ranging drug interactions and potential cardiotoxicity. Indiscriminate unsupervised use can expose the public to serious adverse drug effects. The coronavirus infection which originated from Wuhan, China in December 2019 has turned 72 in to a global catastrophe (1). The virus has been designated as Severe Acute Respiratory 73 Syndrome-Coronavirus-2 (SARS-CoV-2) and the disease caused by the agent as Coronavirus 74 Disease 2019 (COVID-19) (2). WHO pronounced the disease as a pandemic on March 11, 75 2020 (3). The world community has responded to the challenge with resilience and 76 determination (4). There has been a major understanding of the disease as well as the 77 pathogen in a matter of days and weeks rather than years and decades, an unprecedented 78 occurrence in the history of medicine. It has led to the sharing of knowledge, preparedness 79 measures to be implemented, containment measures to mitigate against the virus morbidity 80 & mortality, and collaborative research to quickly address critical gaps in knowledge (5). 81 82 During this COVID-19 pandemic, there have been intense attempts to explore drug therapy 83 for prophylaxis and treatment of SARS-CoV-2 infection (6-9). Several drugs have been 84 identified based on their differing modes of action on the virus and various pathways it 85 traverses and includes several antivirals (lopinavir/ritonavir combination, remdesivir, 86 favipiravir), two antimalarials (chloroquine and hydroxychloroquine), ACE2 inhibitor 87 (losartan), immunosuppressive agents (tocilizumab, leronlimab and corticosteroids), 88 TMPRSS2 inhibitor (camostat mesylate), anti-parasitic drugs (ivermectin & nitazoxanide), 89 Gold-containing drug auranofin, an immunomodulator used in sepsis and leprosy 90 (Sepsivac-Mycobacterium w heat-killed injections), allogeneic PLacental eXpanded (PLX) 91 cells, and convalescent plasma (6-10) ( Table 1) . As of today, there is no medication or 92 vaccine proven to be effective for the treatment or prevention of COVID-19 (11-13). to inhibition of various processes in innate and adaptive immunity (Fig 2) . The drug 177 has an immunoregulatory effect and downregulates pro-inflammatory cytokines 178 namely Interleukin 1 (IL-1), Interleukin-6 (il-6), Interferons (IFNα and IFNγ), tumor 179 necrosis factor (TNF) and B-cell activating factor (BAFF QT interval, which increases to 37% in moderate risk (7-10) score and 73% in those with a 481 high-risk score (≥11). 482 It is proposed that a stepwise action plan be followed up while HCQ is used in patients 483 with COVID-19 ( there-is-no-scientific-evidence-ye. Coronavirus outbreak: ICMR recommends the use of hydroxy-chloroquine 579 for critical COVID-19 cases: Business Today, Lower Parel Coronavirus and chloroquine: Has it been approved in US Chloroquine genius Didier Raoult to save the world from COVID -19. : 34. McChesney EW. Animal toxicity and pharmacokinetics of hydroxychloroquine 647 sulfate Antimalarial agents. Chloroquine, hydroxychloroquine, 649 and quinacrine Use of Hydroxychloroquine in Japan Mechanisms of action of hydroxychloroquine and 653 chloroquine: implications for rheumatology Agents Used to Treat Parasitic Diseases Harrison's Principles of Internal Medicine 656 Quinoline antimalarials: mechanisms of action and resistance and 658 prospects for new agents Antimalarial drug resistance: An overview PfCRT and its role in antimalarial drug 662 resistance The 664 pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum 665 from the western border of Thailand COVID-19 (Novel Coronavirus 694 2019) -recent trends Chloroquine and hydroxychloroquine in 696 the treatment of COVID-19 with or without diabetes: A systematic search and a narrative 697 review with a special reference to India and other developing countries Clinical pharmacokinetics and metabolism of chloroquine Focus on recent advancements Diagnostic accuracy of point-of-care tests for 702 hepatitis C virus infection: a systematic review and meta-analysis SARS-CoV-2 infection in India: A case-control investigation in the time of COVID-19 2020 706 Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 Chloroquine is a potent inhibitor of SARS coronavirus infection and spread Remdesivir and chloroquine 715 effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Hydroxychloroquine, a less toxic 718 derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro In Vitro Antiviral Activity and 721 Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe 722 Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Breakthrough: Chloroquine phosphate has shown apparent 724 efficacy in the treatment of COVID-19 associated pneumonia in clinical studies Ventricular Arrhythmia Risk Due to 727 Clinical and 733 microbiological effect of a combination of hydroxychloroquine COVID-19 patients with at least a six-day follow up: A pilot observational study A pilot study of 738 hydroxychloroquine in the treatment of patients with common coronavirus disease-19 739 (COVID-19) Efficacy of hydroxychloroquine in 741 patients with COVID-19: results of a randomized clinical trial Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-745 19 Chloroquine diphosphate in two different dosages as adjunctive 747 therapy of hospitalized patients with the severe respiratory syndrome in the context of 748 coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-749 blinded, phase IIb clinical trial (CloroCovid-19 Study) No 752 evidence of rapid antiviral clearance or clinical benefit with the combination of 753 hydroxychloroquine and azithromycin in patients with severe COVID-19 infection No evidence 756 of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection 757 with oxygen requirement: results of a study using routinely collected data to emulate a 758 target trial The RECOVERY Trial Reports on Hydroxychloroquine Hydroxychloroquine in patients 764 with mainly mild to moderate coronavirus disease 2019: open-label, randomized controlled 765 trial chloroquine & Google translator: How Medanta treated 771 Italians with coronavirus. ThePrint Incidence of cancer in a 776 cohort of patients with primary Sjogren's syndrome Increased Incidence of Gastrointestinal Side 779 Effects in Patients Taking Hydroxychloroquine: A Brand-related Issue? Heart conduction disorders related to antimalarials toxicity: an analysis of 783 electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue 784 diseases Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature Severe hydroxychloroquine myopathy. Muscle 789 Nerve Hydroxychloroquine retinopathy -791 implications of research advances for rheumatology care The molecular basis of chloroquine block of the inward rectifier 798 Antimalarial 800 myopathy: an underdiagnosed complication? A prospective longitudinal study of 119 801 patients Infectious diseases related to travel. Malaria.: CDC. Centers for 803 Azithromycin and the risk of 807 cardiovascular death Cardiac risks associated with 809 antibiotics: azithromycin and levofloxacin Azithromycin/chloroquine 814 combination does not increase cardiac instability despite an increase in monophasic action 815 potential duration in the anesthetized guinea pig Chloroquine for Uncomplicated Plasmodium falciparum Malaria Is Well Tolerated and 822 Causes Similar QT Interval Prolongation as Standard-Dose Chloroquine in Children Development and validation of a risk score to predict QT interval prolongation in 826 hospitalized patients Cardiac Complications of Chloroquine-Bas Therapy. Expert Opinion / 828 Drug-induced QT interval prolongation: 832 mechanisms and clinical management Hydroxychloroquine in the management of 836 critically ill patients with COVID-19: the need for an evidence base The QT 838 interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin